Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sema4 Holdings Corp (NQ: SMFR )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sema4 Holdings Corp

< Previous 1 2 3 4 5 Next >
Sema4 Holdings Corp. (NASDAQ: SMFR) Long Term Shareholder Notice: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 02/08/2023 -- An investigation was announced for current long-term investors in shares of Sema4 Holdings Corp. (NASDAQ: SMFR) concerning potential breaches of fiduciary... 
Via SBWire
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
Via Benzinga
Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance
From GeneDx Holdings Corp.
Via GlobeNewswire
Sema4 Holdings's Return on Invested Capital Overview
Via Benzinga
What To Know About Goldman Sachs's Downgrade of Sema4 Holdings
Via Benzinga
Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Sema4|GeneDx President & Chief Executive Officer, Katherine Stueland, to deliver presentation 
From Sema4
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 116 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  Monday saw 196 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 127 companies set new 52-week lows. 
Via Benzinga
ConocoPhillips To Rally Over 30%? Here Are 10 Other Price Target Changes For Wednesday
Barclays raised ConocoPhillips (NYSE: COP) price target from $135 to $151. Barclays analyst Jeanine Wai maintained an Overweight rating on the stock. ConocoPhillips shares fell 3.2% to close at $115.61... 
Via Benzinga
New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU
Data underscores the value of mitochondrial DNA testing and the opportunity to improve health outcomes for critically ill newborns with early medical intervention 
From Sema4
Via GlobeNewswire
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
From Sema4
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
  On Friday, 72 companies hit new 52-week lows. 
Via Benzinga
NASDAQ:SMFR Investor Alert: Deadline on November 7, 2022 in Lawsuit Against Sema4 Holdings Corp.
San Diego, CA -- (SBWIRE) -- 11/09/2022 -- The Shareholders Foundation announced that a deadline is coming up on November 7, 2022 in the lawsuit filed for certain investors of Sema4 Holdings Corp.... 
Via SBWire
Deadline Alert: Sema4 Holdings Corp. (SMFR, SMFRW) Class Action - Bronstein, Gewirtz & Grossman, LLC, A Prominent Firm, Encourages Shareholders of Last Few Hours to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's session, 107 stocks hit new 52-week lows. 
Via Benzinga
Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 70 companies set new 52-week lows. 
Via Benzinga
SMFR FINAL DEADLINE TODAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Sema4 Holdings Corp. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SMFR, SMFRW
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million. 
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bed Bath & Beyond, Sema4, Medtronic, and Palantir and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SMFR FINAL DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Sema4 Holdings Corp. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SMFR, SMFRW
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
SEMA4 HOLDINGS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Sema4 Holdings Corp. - SMFR
From Kahn Swick & Foti, LLC
Via Business Wire
Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022
From Sema4
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kohl’s, Bed Bath & Beyond, Sema4, and Medtronic and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies
Guideline adoption can help end the diagnostic odyssey experienced by many families 
From Sema4
Via GlobeNewswire
ROSEN, A TOP RANKED FIRM, Encourages Sema4 Holdings Corp. Investors With Losses Over $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action - SMFR, SMFRW
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns
From Sema4
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kohl’s, Bed Bath & Beyond, Sema4, and Medtronic and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels
Exome and genome tests report 30% fewer inconclusive results and a higher diagnostic yield compared to multi-gene panel tests; research to be presented at American Society of Human Genetics Annual... 
From Sema4
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.